Loading...
NPI 1073776860 · Lubbock, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Microgendx, LLC is a clinical medical laboratory provider located in Lubbock, Texas. This profile covers 16 Medicare and 34 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Microgendx, LLC |
| Address | 6901 Quaker Ave Ste 200 |
| City | Lubbock |
| State | TX |
| ZIP | 79413 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | July 2, 2008 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4.6M |
| Medicaid | $2.1M |
MicroGenDX, LLC’s billing mix is centered on high-complexity molecular infectious disease testing: the proprietary PLA code 0112U ($4.1M Medicare revenue) represents the lab’s signature MicroGenDX® qPCR & NGS test for bacterial and fungal identification and resistance, while a large share of remaining Medicare and Medicaid activity uses amplified nucleic acid probe and multiplex NAATs (examples include 87801, 87636, 87631). This combination of a single, lab-specific sequencing product plus broad NAAT panels indicates the operation functions as a specialized commercial molecular laboratory that pairs a proprietary offering with high-throughput infectious disease screening services.
Medicare revenue is highly concentrated: the provider reports $4.6M in total Medicare revenue and its precomputed top-three Medicare codes account for 98.5% of that Medicare revenue, with 0112U alone reported as $4.1M (89.2% of this provider's total Medicare revenue). That concentration signals heavy dependence on the PLA test for Medicare-funded activity and exposes Medicare revenue to changes in coverage or reimbursement for 0112U.
By contrast, Medicaid billing is more distributed: total Medicaid revenue is $2.1M and the precomputed top-three Medicaid codes account for 42.4% of Medicaid revenue. The largest Medicaid code is U0004 ($444.6K, 21.2% of Medicaid revenue) followed by 87799 ($227.4K, 10.8%) and 87900 ($220K, 10.5%), showing the provider’s Medicaid business uses a broader mix of NAAT and resistance/quantification codes rather than a single dominant PLA.
On payer mix, Medicare ($4.6M) is the larger single source relative to Medicaid ($2.1M), so the provider’s overall Medicare footprint exceeds its Medicaid footprint while both payers contribute material revenue streams. This dual-payer profile means commercial exposure to Medicare policy changes will have an outsized effect on total revenue, while Medicaid activity provides diversification across many molecular tests.
Competitive standing for the Medicare flagship service is notable: 0112U ranks #1 of 2 providers nationally (100th percentile) but is characterized in the source as "typical, unremarkable volume for this code," which suggests MicroGenDX is a leading reporter of this PLA simply because very few providers bill it nationally. Additional Medicare codes such as 87801 (rank #19 of 561, 97th percentile) and 87636 (rank #60 of 2192, 97th percentile) indicate a strong national presence in multiplex NAATs alongside the PLA.
State-level Medicaid rankings show market-leading positions on several codes: 87799 (rank #2 of 38, 97th percentile) and 87900 (rank #2 of 8, 86th percentile) indicate top-tier in-state volumes for resistance/quantification services, while 87482 ranks #1 of 8 in-state (100th percentile) and is described as "notably above typical state volume for this code." These ranks point to MicroGenDX being a highly visible Medicaid lab vendor for a range of molecular diagnostics in Texas.
There are limited statistical outliers embedded in the profile: some Medicaid codes are flagged as "notably above typical" state volume (for example 87500 is noted as "notably above typical state volume for this code" in the Medicaid listing and 87482 is 100th percentile and explicitly called "notably above typical state volume"), while several high-percentile Medicare ranks (including 0112U at 100th percentile) are still labeled "typical, unremarkable volume," reflecting a small national denominator for certain specialized PLA or niche codes rather than anomalous billing intensity. Analysts should therefore interpret percentile ranks together with the plain-English labels provided rather than treating high percentiles alone as evidence of unusual utilization.
MicroGenDX’s NPI was enumerated on 2008-07-02 (~18 years ago), indicating a long tenure as an enrolled clinical medical laboratory. That sustained enrollment combined with a proprietary PLA offering and broad NAAT volumes suggests an established commercial lab model focused on patented/unique molecular assays paired with high-throughput infectious disease testing.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
16 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 0112U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0112U for the… | 11,700 | $350 | $4.1M |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 5,190 | $70 | $358K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 450 | $140 | $62.6K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 190 | $140 | $26.3K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 20 | $410 | $8.6K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 170 | $50 | $8.5K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 230 | $30 | $8K |
| 89051 | The lab analyst performs the technical lab steps to analyze a body fluid, excluding blood, with a cell count and a differential count to measure the amounts of white blood cells present. | 1,040 | $10 | $5.2K |
| 86140 | The lab analyst performs the technical lab test to analyze a specimen, typically serum, for the presence of C reactive protein. | 970 | $10 | $4.8K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 40 | $70 | $2.7K |
Showing 1–10 of 16
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 16 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
16 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 0112U | 1 | 10 | 5,890 | $350 | $2M |
| 87631 | 18 | 90 | 50 | $140 | $90.1K |
| 87801 | 6 | 120 | 170 | $70 | $86.5K |
| 87481 | 193 | 270 | 150 | $30 | $68.8K |
| U0004 | 12 | 20 | 50 | $70 | $40.4K |
| 87636 | 3 | 160 | 20 | $140 | $31.1K |
| 87641 | 95 | 170 | 80 | $30 | $23.2K |
| U0005 | 53 | 70 | 110 | $20 | $22.3K |
| 87500 | 68 | 190 | 80 | $30 | $21.7K |
| 87507 | 7 | 10 | 30 | $360 | $17.1K |
Showing 1–10 of 16
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
34 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 6,740 | $70 | $444.6K |
| 87799 | The lab analyst performs a test to quantify infection with an infectious agent, not otherwise specified in another code, using a nucleic acid probe technique. Use this code if you know the laboratory… | 25,270 | $10 | $227.4K |
| 87900 | The lab analyst measures a patient’s susceptibility or resistance to drugs aimed at a virus. The test predicts the behavior of the phenotype based on comparing patient data to regularly updated… | 7,100 | $30 | $220K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 17,490 | $10 | $174.9K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 10,320 | $20 | $165.1K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 14,450 | $10 | $144.5K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 14,830 | $10 | $133.4K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 7,120 | $10 | $71.2K |
| 87482 | The lab analyst performs a test to quantify infection with Candida species using nucleic acid probe technique. | 5,620 | $10 | $67.4K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 8,050 | $10 | $64.4K |
Showing 1–10 of 34
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
34 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 78 | 120 | 340 | $120 | $422K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 55 | 160 | 200 | $280 | $321.8K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 16 | 100 | 470 | $50 | $319.1K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 8 | 240 | 420 | $30 | $296.8K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 110 | 140 | 180 | $60 | $215.9K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 43 | 150 | 320 | $20 | $184K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 8 | 110 | 360 | $40 | $174.9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 85 | 260 | 640 | $20 | $137.2K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 16 | 20 | 90 | $120 | $132K |
| 87512 | The lab analyst performs a test to quantify infection with Gardnerella vaginalis using nucleic acid probe technique. Gardnerella vaginalis, typically causes bacterial vaginosis, an infection of the… | 2 | 10 | 510 | $20 | $126.7K |
Showing 1–10 of 34
Other providers in the same ZIP code as Microgendx, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Omar Shoukfeh | TX | Ophthalmology Physician | $350.3K | $0 |
| Mark Sherman | TX | Ophthalmology Physician | $300.9K | $1.4K |
| Michael Mendez | TX | Family Medicine Physician | $232.3K | $0 |
| Zuhair Shihab | TX | Ophthalmology Physician | $210K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.